Neuroinflammation in Alzheimer's Disease: Are NSAIDs and Selective COX-2 Inhibitors the Next Line of Therapy?

摘要

Alzheimer's disease (AD) is currently treated with cholinergic and glutamatergic therapies, which provide symptomatic benefit but do not reverse the underlying pathology or cognitive deficits. The prevalence of AD is expected to triple over the next 50 years, creating an urgency to develop effective "disease-modifying" therapies to reduce the economic burden of this devastating disorder. One of the main areas of therapeutic focus has been an anti-inflammatory strategy based on an inflammatory hypothesis of AD.